Tales from the Heart

Lisa Salberg welcomes Dr. Sabahat Bokhari to celebrate the launch of a new HCMA Recognized Center of Excellence at Robert Wood Johnson University Hospital. They discuss why accurately diagnosing the cause of a thickened heart matters and how imaging, genetics and a multidisciplinary team can help patients find the right path to personalized care.

 

This conversation was recorded October 2, 2026

Lisa Salberg talks with Jasmine Patel, Dr. Michael Ayers and Alan Russell of Edgewise Therapeutics about the science behind EDG-7500 and its unique mechanism of action. They break down how this investigational therapy is designed to fine-tune heart contraction and improve relaxation, and what researchers hope it could mean for people with HCM.

 

This conversation was recorded October 1, 2026

Lisa Salberg and Dr. Alex de Feria take a closer look at atrial fibrillation in people with HCM, from recognizing symptoms and reducing stroke risk to medications, cardioversion and newer ablation techniques. They also discuss the rapidly expanding HCM treatment toolbox and why specialized care matters.

 

This conversation was recorded September 24, 2026

Lisa Salberg is joined by HCMA Ambassadors Debra Rafson and Joey Graham to explore an exciting new era in HCM, from expanding clinical trials and treatment options to the new Hearts and Minds Mental Health Network. They also share why connection, community and the upcoming HCMA Annual Meeting matter so much to people living with HCM.

 

This conversation was recorded September 18, 2026.

Lisa Salberg and Dr. Martin Maron explore how extended heart monitoring is uncovering arrhythmias that may go undetected during traditional short-term monitoring. They also discuss A-Fib, today’s options for treating obstruction and emerging research targeting fibrosis in HCM.

 

Conversation recorded Sept. 11, 2026

Lisa Salberg and Dr. Anjali Owens break down promising new clinical trial results for EDG-7500, an investigational therapy for both obstructive and nonobstructive HCM. They explain how the drug may improve symptoms and heart relaxation while potentially offering a different safety and monitoring profile from current targeted therapies.

Conversation recorded Sept. 4, 2026.

Lisa Salberg and Dr. Harry Lever explore atrial fibrillation in HCM, from recognizing risk and monitoring heart rhythms to medications, cardioversion and evolving treatment options. They also discuss generic drug quality, emerging HCM therapies and how decades of progress are giving patients more tools than ever before.

 

Conversation was recorded on Sept. 4, 2026.

Live from ESC in Munich, Lisa Salberg and Dr. Martin Maron unpack groundbreaking results from the ACACIA-HCM trial and what they could mean for people with nonobstructive HCM. They discuss improvements in symptoms and exercise capacity, potential changes in heart structure, and a possible path toward a long-awaited new treatment option.

Conversation was recorded Aug. 28, 2026

Lisa Salberg and Dr. Michael Ayres discuss how patients and families can recognize changing HCM symptoms and know when to call their care team or seek urgent help. They also tackle back-to-school planning, beta blockers, cardiac scarring, autonomic symptoms and the changing HCM treatment toolbox.

 

Conversation recorded Aug. 21, 2026

Lisa Salberg and Dr. Martin Maron take a fresh look at the long-standing role of beta blockers in HCM and how newer myosin inhibitors are changing the treatment conversation. They also discuss upcoming clinical data, fibrosis, symptom changes, and how patients can better navigate evolving care.

 

This conversation was recorded Aug. 14, 2026